+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are evaluating the use of antiplatelet therapy, specifically Aspirin 75 mg daily, to prevent major adverse cardiovascular and cerebrovascular events MACE in patients who have survived intracerebral haemorrhage ICH. This Phase 3, randomized, placebo-controlled, triple-blinded clinical trial plans to recruit 5676 patients aged 18 to 99 years across 50 stroke centers in India. The study aims to address the safety and effectiveness of starting antiplatelet monotherapy after ICH, a question not yet resolved by large trials. Participants will be randomly assigned to receive either daily Aspirin 75 mg or a matching placebo, both alongside standard secondary prevention care. The medication and follow-up duration depend on recruitment timing those recruited in the first year will take the medication for up to three years or until an event occurs, while those recruited later will take it for a minimum of six months with matching follow-up. The total trial duration is three years, with recruitment lasting 2.5 years and follow-up continuing until the study ends. The investigational products are centrally manufactured and dispensed yearly at each site. Participants will undergo face-to-face visits every three months to receive the medication and return unused tablets, with monthly phone calls to monitor adherence and detect any events. Brain imaging by CT or MRI will be done as part of routine care at baseline and if events occur. Researchers will collect clinical data, medication adherence, and functional assessments such as the modified Rankin Scale. Safety monitoring includes event adjudication and follow-up until three years or until withdrawal, death, or event occurrence. The primary outcome is the occurrence of MACE over three years.

Age: 18Years - 99YearsAll GendersPhase 3
33 locations